Quick Answer
Entera Bio Ltd. reported Cash and Equivalents of $7.11 million for fiscal year 2025.
Entera Bio Ltd. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $7.11M | -17.9% |
| 2024 | $8.66M | -21.4% |
| 2023 | $11.02M | -10.5% |
| 2022 | $12.31M | -50.6% |
| 2021 | $24.89M | +189.7% |
| 2020 | $8.59M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.57M | +24.0% | -21.0% |
| June 30, 2025 | $10.86M | +19.9% | -13.6% |
| March 31, 2025 | $12.57M | +36.8% | +45.2% |
| December 31, 2024 | $8.66M | -21.4% | +25.2% |
| September 30, 2024 | $6.92M | -8.8% | -23.6% |
| June 30, 2024 | $9.06M | -0.9% | -1.4% |
| March 31, 2024 | $9.19M | -14.0% | -16.6% |
| December 31, 2023 | $11.02M | -10.5% | +45.3% |
- Entera Bio Ltd. showed a decrease of -17.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Entera Bio Ltd.’s cash and equivalents has declined by 17.3% (from $8.59 million to $7.11 million).
- The most recent figure is from Entera Bio Ltd.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: